Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report

The aim of this study was to describe a clinical case of a patient with Alzheimer's disease (AD) in use of an anti-TNF-α agent for rheumatoid arthritis (RA). The patient reported is an 81-year-old Caucasian man and retired teacher, diagnosed with RA in 2008 and AD in 2011. Treatment with donepezil was started in 2011 and the use of etanercept introduced in 2012. He was previously treated with adalimumab in 2010 for 18 months. In 2013, the subject was engaged in a clinical trial to assess a complementary non-pharmacological approach for AD, presenting significant cognitive improvement during the follow-up period. We propose the hypothesis of a synergistic effect of anti-TNF-α medication used for the treatment of RA as the cause of the improvement in cognitive response observed. These findings could suggest a possible use of this drug class in the therapeutic management of AD.

Saved in:
Bibliographic Details
Main Authors: Camargo,Carlos Henrique Ferreira, Justus,Filipe Fernandes, Retzlaff,Giuliano, Blood,Marcelo Rezende Young, Schafranski,Marcelo Derbli
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento 2015
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642015000200196
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1980-57642015000200196
record_format ojs
spelling oai:scielo:S1980-576420150002001962015-07-02Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case reportCamargo,Carlos Henrique FerreiraJustus,Filipe FernandesRetzlaff,GiulianoBlood,Marcelo Rezende YoungSchafranski,Marcelo Derbli TNF-α Alzheimer's disease rheumatoid arthritis The aim of this study was to describe a clinical case of a patient with Alzheimer's disease (AD) in use of an anti-TNF-α agent for rheumatoid arthritis (RA). The patient reported is an 81-year-old Caucasian man and retired teacher, diagnosed with RA in 2008 and AD in 2011. Treatment with donepezil was started in 2011 and the use of etanercept introduced in 2012. He was previously treated with adalimumab in 2010 for 18 months. In 2013, the subject was engaged in a clinical trial to assess a complementary non-pharmacological approach for AD, presenting significant cognitive improvement during the follow-up period. We propose the hypothesis of a synergistic effect of anti-TNF-α medication used for the treatment of RA as the cause of the improvement in cognitive response observed. These findings could suggest a possible use of this drug class in the therapeutic management of AD.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e EnvelhecimentoDementia & Neuropsychologia v.9 n.2 20152015-06-01info:eu-repo/semantics/reporttext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642015000200196en10.1590/1980-57642015DN92000015
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Camargo,Carlos Henrique Ferreira
Justus,Filipe Fernandes
Retzlaff,Giuliano
Blood,Marcelo Rezende Young
Schafranski,Marcelo Derbli
spellingShingle Camargo,Carlos Henrique Ferreira
Justus,Filipe Fernandes
Retzlaff,Giuliano
Blood,Marcelo Rezende Young
Schafranski,Marcelo Derbli
Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
author_facet Camargo,Carlos Henrique Ferreira
Justus,Filipe Fernandes
Retzlaff,Giuliano
Blood,Marcelo Rezende Young
Schafranski,Marcelo Derbli
author_sort Camargo,Carlos Henrique Ferreira
title Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
title_short Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
title_full Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
title_fullStr Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
title_full_unstemmed Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report
title_sort action of anti-tnf-α drugs on the progression of alzheimer's disease: a case report
description The aim of this study was to describe a clinical case of a patient with Alzheimer's disease (AD) in use of an anti-TNF-α agent for rheumatoid arthritis (RA). The patient reported is an 81-year-old Caucasian man and retired teacher, diagnosed with RA in 2008 and AD in 2011. Treatment with donepezil was started in 2011 and the use of etanercept introduced in 2012. He was previously treated with adalimumab in 2010 for 18 months. In 2013, the subject was engaged in a clinical trial to assess a complementary non-pharmacological approach for AD, presenting significant cognitive improvement during the follow-up period. We propose the hypothesis of a synergistic effect of anti-TNF-α medication used for the treatment of RA as the cause of the improvement in cognitive response observed. These findings could suggest a possible use of this drug class in the therapeutic management of AD.
publisher Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento
publishDate 2015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642015000200196
work_keys_str_mv AT camargocarloshenriqueferreira actionofantitnfadrugsontheprogressionofalzheimersdiseaseacasereport
AT justusfilipefernandes actionofantitnfadrugsontheprogressionofalzheimersdiseaseacasereport
AT retzlaffgiuliano actionofantitnfadrugsontheprogressionofalzheimersdiseaseacasereport
AT bloodmarcelorezendeyoung actionofantitnfadrugsontheprogressionofalzheimersdiseaseacasereport
AT schafranskimarceloderbli actionofantitnfadrugsontheprogressionofalzheimersdiseaseacasereport
_version_ 1756434472634417152